ID30032A - Formulasi farmasi - Google Patents

Formulasi farmasi

Info

Publication number
ID30032A
ID30032A IDW00200101527A ID20011527A ID30032A ID 30032 A ID30032 A ID 30032A ID W00200101527 A IDW00200101527 A ID W00200101527A ID 20011527 A ID20011527 A ID 20011527A ID 30032 A ID30032 A ID 30032A
Authority
ID
Indonesia
Prior art keywords
pharmaceutical formulation
formulation
pharmaceutical
Prior art date
Application number
IDW00200101527A
Other languages
English (en)
Inventor
Terrence C Dahl
Lung-Chi J Yuan
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/211,613 external-priority patent/US6635278B1/en
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of ID30032A publication Critical patent/ID30032A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IDW00200101527A 1998-12-15 1999-12-14 Formulasi farmasi ID30032A (id)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11240398P 1998-12-15 1998-12-15
US09/211,613 US6635278B1 (en) 1998-12-15 1998-12-15 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
ID30032A true ID30032A (id) 2001-11-01

Family

ID=26809911

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW00200101527A ID30032A (id) 1998-12-15 1999-12-14 Formulasi farmasi

Country Status (18)

Country Link
EP (1) EP1140114B1 (id)
JP (1) JP4750946B2 (id)
KR (1) KR100624214B1 (id)
CN (2) CN100361664C (id)
AR (1) AR021670A1 (id)
AT (1) ATE298576T1 (id)
AU (1) AU759869B2 (id)
BR (1) BRPI9916820B8 (id)
CA (1) CA2355239C (id)
CO (1) CO5261557A1 (id)
DE (1) DE69926012T2 (id)
ES (1) ES2245130T3 (id)
ID (1) ID30032A (id)
MY (1) MY126526A (id)
NZ (1) NZ511855A (id)
TR (1) TR200101746T2 (id)
TW (1) TWI230618B (id)
WO (1) WO2000035460A2 (id)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020119443A1 (en) * 2000-07-21 2002-08-29 Gilead Sciences, Inc. Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same
IL159326A0 (en) * 2001-07-31 2004-06-01 Lundbeck & Co As H Crystalline composition containing escitalopram
KR101101962B1 (ko) * 2002-11-12 2012-01-02 티안진 디실리 인베스트먼트 홀딩 그룹, 리미티드 새로운 결정 형태를 가진 아데포비어 디피복실의 제조 방법
ES2752773T3 (es) 2003-06-13 2020-04-06 Idh Holding Aps Tratamiento de los síntomas asociados a la vaginosis bacteriana
ITMI20071594A1 (it) 2007-08-02 2009-02-03 Solmag Spa Forma cristallina monoidrata di adefovir dipivoxil
KR20100031045A (ko) 2008-09-11 2010-03-19 씨제이제일제당 (주) 아데포비어 디피복실의 정제방법
EP2332941A4 (en) * 2008-09-17 2012-08-08 Cj Cheiljedang Corp STABILIZED SOLIDS DISPERSION FROM ADEFOVIR-DIPIVOXIL AND PROCESS FOR THE PRODUCTION THEREOF
KR101089620B1 (ko) * 2009-07-20 2011-12-06 경희대학교 산학협력단 무수결정형 아데포비어 디피복실 및 이온성 액체를 사용한 이의 제조 방법
MY162940A (en) 2009-08-19 2017-07-31 Eisai R&D Man Co Ltd Quinoline derivative-containing pharmaceutical composition
EP2343056A1 (en) 2009-12-30 2011-07-13 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Producing stable adefovir dipivoxil solid dispersions
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
WO2017112894A1 (en) * 2015-12-22 2017-06-29 X4 Pharmaceuticals, Inc. Methods for treating immunodeficiency disease
EP4696303A1 (en) * 2024-08-14 2026-02-18 Bonutra AG All natural granulate

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58201726A (ja) * 1982-05-18 1983-11-24 Meiji Seika Kaisha Ltd 安定な製剤の製造法
CS263952B1 (en) * 1985-04-25 1989-05-12 Holy Antonin Remedy with antiviral effect
US4704365A (en) * 1986-02-24 1987-11-03 Abbott Laboratories Composition and method for stabilization of dinucleotides
CA2035841C (en) * 1990-02-22 1996-02-13 Harry B. Demopoulos Storage-stable glucosamine sulphate oral dosage forms and methods for their manufacture
EP0481214B1 (en) * 1990-09-14 1998-06-24 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Prodrugs of phosphonates
JPH0825905B2 (ja) * 1990-11-20 1996-03-13 武田薬品工業株式会社 医薬固形組成物用安定化剤および安定化方法
HU9203780D0 (en) * 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
JP3254219B2 (ja) * 1993-01-19 2002-02-04 ワーナー−ランバート・コンパニー 安定な経口用のｃｉ−９８１製剤およびその製法
US5817336A (en) * 1993-04-02 1998-10-06 Orion-Yhtyma Oy Composition containing selegiline
JP2974550B2 (ja) * 1993-06-01 1999-11-10 ビオフェルミン製薬株式会社 経口投与用固体組成物
US5919776A (en) * 1996-12-20 1999-07-06 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity
JP2762998B2 (ja) * 1997-04-25 1998-06-11 武田薬品工業株式会社 医薬固形組成物用安定化剤および安定化方法
JPH114666A (ja) * 1997-06-17 1999-01-12 Otsuka Pharmaceut Co Ltd マグネシウム補給発泡剤組成物
TR200000224T2 (tr) * 1997-07-25 2000-07-21 Gilead Sciences, Inc. Nükleotid analog kompozisyonlar.

Also Published As

Publication number Publication date
AU759869B2 (en) 2003-05-01
WO2000035460A2 (en) 2000-06-22
WO2000035460A3 (en) 2000-11-09
JP4750946B2 (ja) 2011-08-17
EP1140114B1 (en) 2005-06-29
KR20010080765A (ko) 2001-08-22
BRPI9916820B8 (pt) 2023-04-25
ATE298576T1 (de) 2005-07-15
CN1330547A (zh) 2002-01-09
CA2355239A1 (en) 2000-06-22
MY126526A (en) 2006-10-31
DE69926012D1 (de) 2005-08-04
AU2361300A (en) 2000-07-03
TWI230618B (en) 2005-04-11
CN100361664C (zh) 2008-01-16
CO5261557A1 (es) 2003-03-31
EP1140114A2 (en) 2001-10-10
AR021670A1 (es) 2002-07-31
BRPI9916820A2 (pt) 2001-10-30
CN1202829C (zh) 2005-05-25
JP2002532429A (ja) 2002-10-02
ES2245130T3 (es) 2005-12-16
DE69926012T2 (de) 2006-05-04
TR200101746T2 (tr) 2001-12-21
KR100624214B1 (ko) 2006-09-18
NZ511855A (en) 2003-07-25
HK1040488A1 (en) 2002-06-14
BRPI9916820B1 (pt) 2018-04-03
CN1682743A (zh) 2005-10-19
CA2355239C (en) 2008-03-18

Similar Documents

Publication Publication Date Title
NO20012915D0 (no) Ny farmasöytisk formulering
ID24654A (id) Formulasi farmasi omeprazola
ID23299A (id) Formulasi-formulasi farmasi
DK1073417T3 (da) Farmaceutisk aerosolformulering
ID27415A (id) Komposisi farmaseutik
FIU20000164U0 (fi) Uusi farmaseuttinen formulaatio
ID28698A (id) Formulasi antiparasit
ID29635A (id) Formulasi mikrokapsul
ID29262A (id) Komposisi farmasi
DK1466615T3 (da) Farmaceutisk præparat
ID27201A (id) Komposisi farmasi
ID27655A (id) Formulasi mikrokapsul
ID30032A (id) Formulasi farmasi
IS2515B (is) Lyfjasamsetningar
AR025867A1 (es) Formulacion portasdora farmaceutica
EE200000330A (et) Farmatseutilised kompositsioonid
EP1124557A4 (en) Pharmaceutical composition
ID26215A (id) Komposisi farmasi
NO20004816D0 (no) Ny farmasøytisk formulering
NO994436D0 (no) Farmasöytiske sammensetninger
SE9803952D0 (sv) Pharmaceutical formulation
SE9600141D0 (sv) Pharmaceutical formulation
SE9800766D0 (sv) Formulation
SE9800170D0 (sv) Formulation
SE9800330D0 (sv) Pharmaceutical compositions